MyMD Pharmaceuticals (MYMD) Stock Price, News & Analysis

Company Overview

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.09 to $0.18
• 52-Week Range: $1.75 to $63.90
• Volume: 22.40 million shs
• Average Volume: 134,123 shs
• Market Capitalization: $242.45 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MYMD Stock Analysis - Frequently Asked Questions

How have MYMD shares performed this year?

MyMD Pharmaceuticals' stock was trading at $1.15 on January 1st, 2025. Since then, MYMD stock has decreased by 91.1% and is now trading at $0.1023.

When did MyMD Pharmaceuticals' stock split?

MyMD Pharmaceuticals's stock reverse split on Thursday, February 15th 2024.The 1-30 reverse split was announced on Thursday, February 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of MyMD Pharmaceuticals?

Shares of MYMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MyMD Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MyMD Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), NOVONIX (NVNXF) and Globant (GLOB).

Company Calendar

• Today: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MYMD
• CIK: 1321834
• Web: www.mymd.com
• Phone: 856-848-8698
• Fax: 856-848-0269
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -179.05%
• Return on Assets: -108.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.62
• Quick Ratio: 0.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.21 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 2,370,000
• Free Float: 2,320,000
• Market Cap: $242.45 thousand
• Optionable: Optionable
• Beta: 2.15